Cargando…
Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer
The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600314/ https://www.ncbi.nlm.nih.gov/pubmed/36290863 http://dx.doi.org/10.3390/curroncol29100586 |
_version_ | 1784816811381882880 |
---|---|
author | Shen, Jing Lian, Xin Guan, Qiu He, Lei Zhang, Fuquan Shen, Jie |
author_facet | Shen, Jing Lian, Xin Guan, Qiu He, Lei Zhang, Fuquan Shen, Jie |
author_sort | Shen, Jing |
collection | PubMed |
description | The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemoradiotherapy at PUMCH (Peking Union Medical College Hospital) were retrospectively studied. Using concurrent chemotherapy (Capecitabine alone or XELOX*2 cycles), radiotherapy (IMRT (intensity-modulated radiation therapy) 45 Gy, 25#, 5 weeks) was delivered with IGRT (image-guided radiotherapy) before the start of each weeks therapy to ensure accuracy and repeatability. A total of 95 patients were enrolled in the study, 93 (97.9%) stage cT3/T4 and 85 (89.5%) stage N+. Of these, 85 patients (89.5%) had a tumor located in the upper 1/3 of the stomach, and 93/95 patients (97.9%) completed neoadjuvant chemoradiation, with 80 patients (84.2%) undergoing stomach resection (58 D2 and 22 D1 gastrostomies). Pathology downstaging was found in 68 patients (85.0%), with 66 patients (82.5%) receiving T downstaging and 56 patients (70.0%) receiving N downstaging. There were 11 individuals (13.8%) who had a pathological complete response (PCR). The average period of follow-up was 44.7 months (19–96 months). The 5-year OS (overall survival), LRFS (local recurrence-free survival), and DMFS (distant metastasis free survival) rates of patients were 47.0% (95% CI: 38.6–55.4), 86.55% (95% CI: 79.1–93.99) and 60.71% (95% CI: 51.49–69.93%), respectively. Thirteen (13.7%) patients had grade 3–4 leukopenia, anemia, and thrombocytopenia, while 9 (9.5%) patients had grade 3–4 anemia, and 5 (5.3%) patients had grade 3–4 thrombocytopenia. PCR was found to be a significant predictive factor for OS in multivariate analysis (HR = 11.211, 95% CI: 1.500–83.813, p = 0.024). The method of using IGRT image-guided IMRT (45 Gy, 25 fractions, 5 weeks) combined with concurrent chemotherapy in patients with locally advanced resectable gastric cancer was equally effective when compared to the clinical efficacy of neoadjuvant chemoradiotherapy, with clinical outcomes achieving equal efficacy, with similar PCR rates and high rates of OS, LRFS, and DMFS, as well as good tolerances of concurrent chemoradiotherapy with acceptable side effects. |
format | Online Article Text |
id | pubmed-9600314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96003142022-10-27 Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer Shen, Jing Lian, Xin Guan, Qiu He, Lei Zhang, Fuquan Shen, Jie Curr Oncol Article The goal of this study was to see how effective and safe neoadjuvant chemoradiation with image-guided IMRT was in patients with locally advanced resectable gastric cancer. Between January 2013 and June 2019, patients with locally advanced (cT3/cT4 or N+) gastric cancer treated with neoadjuvant chemoradiotherapy at PUMCH (Peking Union Medical College Hospital) were retrospectively studied. Using concurrent chemotherapy (Capecitabine alone or XELOX*2 cycles), radiotherapy (IMRT (intensity-modulated radiation therapy) 45 Gy, 25#, 5 weeks) was delivered with IGRT (image-guided radiotherapy) before the start of each weeks therapy to ensure accuracy and repeatability. A total of 95 patients were enrolled in the study, 93 (97.9%) stage cT3/T4 and 85 (89.5%) stage N+. Of these, 85 patients (89.5%) had a tumor located in the upper 1/3 of the stomach, and 93/95 patients (97.9%) completed neoadjuvant chemoradiation, with 80 patients (84.2%) undergoing stomach resection (58 D2 and 22 D1 gastrostomies). Pathology downstaging was found in 68 patients (85.0%), with 66 patients (82.5%) receiving T downstaging and 56 patients (70.0%) receiving N downstaging. There were 11 individuals (13.8%) who had a pathological complete response (PCR). The average period of follow-up was 44.7 months (19–96 months). The 5-year OS (overall survival), LRFS (local recurrence-free survival), and DMFS (distant metastasis free survival) rates of patients were 47.0% (95% CI: 38.6–55.4), 86.55% (95% CI: 79.1–93.99) and 60.71% (95% CI: 51.49–69.93%), respectively. Thirteen (13.7%) patients had grade 3–4 leukopenia, anemia, and thrombocytopenia, while 9 (9.5%) patients had grade 3–4 anemia, and 5 (5.3%) patients had grade 3–4 thrombocytopenia. PCR was found to be a significant predictive factor for OS in multivariate analysis (HR = 11.211, 95% CI: 1.500–83.813, p = 0.024). The method of using IGRT image-guided IMRT (45 Gy, 25 fractions, 5 weeks) combined with concurrent chemotherapy in patients with locally advanced resectable gastric cancer was equally effective when compared to the clinical efficacy of neoadjuvant chemoradiotherapy, with clinical outcomes achieving equal efficacy, with similar PCR rates and high rates of OS, LRFS, and DMFS, as well as good tolerances of concurrent chemoradiotherapy with acceptable side effects. MDPI 2022-10-06 /pmc/articles/PMC9600314/ /pubmed/36290863 http://dx.doi.org/10.3390/curroncol29100586 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shen, Jing Lian, Xin Guan, Qiu He, Lei Zhang, Fuquan Shen, Jie Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title | Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title_full | Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title_fullStr | Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title_full_unstemmed | Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title_short | Neoadjuvant Chemo-Radiation Using IGRT in Patients with Locally Advanced Gastric Cancer |
title_sort | neoadjuvant chemo-radiation using igrt in patients with locally advanced gastric cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600314/ https://www.ncbi.nlm.nih.gov/pubmed/36290863 http://dx.doi.org/10.3390/curroncol29100586 |
work_keys_str_mv | AT shenjing neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer AT lianxin neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer AT guanqiu neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer AT helei neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer AT zhangfuquan neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer AT shenjie neoadjuvantchemoradiationusingigrtinpatientswithlocallyadvancedgastriccancer |